Results 71 to 80 of about 3,242 (120)

Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors. [PDF]

Oncologist
do Amaral PS, Beckermann KE, Gordetsky JB, Chang SS, Joyce DD, Schaffer K, Luckenbaugh AN, Lambrecht MA, Ryan EG, Barocas DA, Moses KA, Rini BI.   +11 more
europepmc   +1 more source

Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. [PDF]

Oncologist
Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan AC.   +6 more
europepmc   +1 more source

Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm. [PDF]

Oncologist
Marmorino F, Morano F, Canciello MA, Rossi P, Gandini A, Laurent-Puig P, Ugolini C, Martinelli E, Cremolini C.   +8 more
europepmc   +1 more source

Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV). [PDF]

Microorganisms
Acosta CJ, Nordio F, Kpamegan E, Moss KJ, Kumar P, Hirata K.   +5 more
europepmc   +1 more source

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients. [PDF]

Oncologist
Guerrero P, Albarrán V, González-Merino C, García de Quevedo C, Sotoca P, Chamorro J, Rosero DI, Barrill A, Alía V, Calvo JC, Moreno J, Pérez de Aguado P, Álvarez-Ballesteros P, San Román M, Serrano JJ, Soria A, Olmedo ME, Saavedra C, Cortés A, Gómez A, Lage Y, Ruiz Á, Ferreiro MR, Longo F, Guerra E, Martínez-Delfrade Í, Garrido P, Gajate P.   +27 more
europepmc   +1 more source

No longer uncertain: the validation of tenebrionid insects as hosts of <i>Blattambidensovirus incertum1</i> isolates by phylogeny and infection studies. [PDF]

J Gen Virol
Lim FS, González-Cabrera J, Jehle JA, Lefebvre T, Wennmann JT.   +4 more
europepmc   +1 more source

Vorwort

Zeitschrift für Rezensionen zur Germanistischen Sprachwissenschaft, 2015
doaj   +1 more source

PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma. [PDF]

Oncologist
Mohan A, Quingalahua E, Gunchick V, Paul S, Kumar-Sinha C, Crysler O, Zalupski MM, Sahai V.   +7 more
europepmc   +1 more source